Margherita Maffioli
Overview
Explore the profile of Margherita Maffioli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iurlo A, Bucelli C, Intermesoli T, Elena C, DAdda M, Agostani E, et al.
Acta Haematol
. 2024 Sep;
:1-5.
PMID: 39293408
Introduction: Up to 30% of CML patients will require a therapeutic change during follow-up due to intolerance and/or resistance to first-line tyrosine kinase inhibitor (TKI) approach. In this context, bosutinib...
2.
Carretta C, Parenti S, Bertesi M, Rontauroli S, Badii F, Tavernari L, et al.
Leukemia
. 2024 Aug;
38(10):2171-2182.
PMID: 39179669
JAK2V617F is the most recurrent genetic mutation in Philadelphia-negative chronic Myeloproliferative Neoplasms (MPNs). Since the JAK2 locus is located on Chromosome 9, we hypothesized that Chromosome 9 copy number abnormalities...
3.
Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco G, Signori L, et al.
Am J Hematol
. 2024 Jun;
99(8):1550-1559.
PMID: 38841874
The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce...
4.
Coltro G, Capecchi G, Maffioli M, Mannelli F, Mora B, Atanasio A, et al.
Haematologica
. 2024 May;
109(10):3398-3403.
PMID: 38813708
No abstract available.
5.
Kuykendall A, Ball S, Mora B, Mo Q, Al Ali N, Maffioli M, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300593.
PMID: 38484210
Purpose: Ruxolitinib improves splenomegaly and disease-related symptoms in most patients with myelofibrosis (MF), and it has been associated with a survival benefit in higher-risk patients with splenomegaly. Spleen volume reduction...
6.
Zambrotta G, Nicolini F, Assouline S, Busque L, Pungolino E, Abruzzese E, et al.
Am J Hematol
. 2023 Aug;
98(11):1762-1771.
PMID: 37647134
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports...
7.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, et al.
EJHaem
. 2023 Aug;
4(3):679-689.
PMID: 37601878
Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%-20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival...
8.
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, et al.
Leukemia
. 2022 Aug;
36(10):2453-2460.
PMID: 36042316
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (primary MF,...
9.
10.
Maffioli M, Mora B, Ball S, Iurlo A, Elli E, Finazzi M, et al.
Blood Adv
. 2022 Feb;
6(6):1855-1864.
PMID: 35130339
Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria...